Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 106.70M P/E - EPS this Y 8.70% Ern Qtrly Grth -
Income -32.96M Forward P/E -2.58 EPS next Y 12.10% 50D Avg Chg -2.00%
Sales 65.42M PEG - EPS past 5Y - 200D Avg Chg 17.00%
Dividend N/A Price/Book 3.87 EPS next 5Y - 52W High Chg -32.00%
Recommedations 1.90 Quick Ratio 4.85 Shares Outstanding 28.72M 52W Low Chg 244.00%
Insider Own 3.90% ROA -15.32% Shares Float 11.57M Beta 2.09
Inst Own 77.92% ROE -118.91% Shares Shorted/Prior 97.14K/30.93K Price 4.20
Gross Margin 73.56% Profit Margin -50.38% Avg. Volume 10,770 Target Price 17.83
Oper. Margin -28.04% Earnings Date May 8 Volume 7,235 Change 0.96%
About Neuropace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Neuropace, Inc. News
04/17/24 NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
04/04/24 ‘Time to Hit Buy,’ Says Wells Fargo About These 2 Stocks
03/27/24 NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
03/07/24 NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript
03/07/24 NeuroPace Full Year 2023 Earnings: EPS Beats Expectations
03/06/24 Q4 2023 Neuropace Inc Earnings Call
03/05/24 NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
03/05/24 Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio
02/23/24 20 Most Valuable Digital Health Companies In The US
02/15/24 NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
02/07/24 NeuroPace Inc Chief Medical Officer Martha Morrell Sells 17,589 Shares
02/01/24 NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,848 Shares
01/08/24 NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates
12/29/23 NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,402 Shares
12/21/23 NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
12/19/23 NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/04/23 NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
12/01/23 NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
11/21/23 NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
11/07/23 NeuroPace, Inc. (NASDAQ:NPCE) Q3 2023 Earnings Call Transcript
NPCE Chatroom

User Image intratio Posted - 21 hours ago

$NPCE https://www.intratio.com/stock-forecast/NPCE NeuroPace Inc Our algorithm deduces the stock price of this company has a poor outlook for the near future and has a dramatic negative long-term outlook

User Image insiderbuyingselling Posted - 04/27/24

$NPCE new insider selling: 1781 shares. http://insiderbuyingselling.com/?t=NPCE

User Image intratio Posted - 04/24/24

$NPCE https://www.intratio.com/stock-forecast/NPCE Our machine learning model is forecasting the value of this stock has an unfavorable short-term setup and is facing massive downsides in the longer term

User Image insiderbuyingselling Posted - 04/23/24

$NPCE new insider selling: 64653 shares. http://insiderbuyingselling.com/?t=NPCE

User Image insiderbuyingselling Posted - 04/18/24

$NPCE new insider selling: 16992 shares. http://insiderbuyingselling.com/?t=NPCE

User Image Stock_Titan Posted - 04/17/24

$NPCE NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 https://www.stocktitan.net/news/NPCE/neuro-pace-to-report-first-quarter-2024-financial-results-on-may-8-xm5job27uax0.html

User Image Scoops1212 Posted - 04/16/24

$NPCE Conferences hardly EVER EVER spike the price, y’all!! It’s going to be about the economy getting back leadership under President Trump!!

User Image insiderbuyingselling Posted - 04/15/24

$NPCE new insider selling: 485000 shares. http://insiderbuyingselling.com/?t=NPCE

User Image tymega2020 Posted - 04/10/24

@Joaquin_Guzman5 please let me know also $NPCE

User Image Joaquin_Guzman5 Posted - 04/05/24

Thx to $SWAV, $NPCE and $TMDX up nice 😊!

User Image TipRanks Posted - 04/04/24

‘Time to Hit Buy,’ Says Wells Fargo About These 2 Stocks https://www.tipranks.com/news/article/time-to-hit-buy-says-wells-fargo-about-these-2-stocks $GDRX $NPCE

User Image Stock_Titan Posted - 03/27/24

$NPCE NeuroPace to Present at the Needham 23rd Annual Healthcare Conference https://www.stocktitan.net/news/NPCE/neuro-pace-to-present-at-the-needham-23rd-annual-healthcare-cnfsm4voaxua.html

User Image Joaquin_Guzman5 Posted - 03/21/24

@BstnGeorge checkout $npce $HIMS

User Image cheating_stock_investor Posted - 03/14/24

$NPCE the analyst know this is good. I know this is good, but the market doesnt believe it is good until they start seeing numbers. Management played it conservative by giving hardly any growth in guidance vs last years growth. They got a lot of good things going on yet they dont want to share what it can do until the sales are there

User Image GuerillaStockTrading Posted - 03/10/24

Earnings smash predictions. NeuroPace $NPCE defies odds with a 41% revenue surge. Discover how they achieved this remarkable growth. https://www.guerillastocktrading.com/neuropace-driving-innovation-and-growth-in-epilepsy-treatment/

User Image jessevandez Posted - 03/08/24

$NPCE I just had this device implanted to fight my epilepsy. It was nearly my only option left. I'm currently in the midst of recovering from surgery. Thank you all for supporting this stock and, in turn me in this journey.

User Image swingingtech Posted - 03/06/24

$NPCE https://wallstreetwaves.com/npce-stock-earnings-neuropace-beats-eps-beats-revenue-for-q4-2023/

User Image Joaquin_Guzman5 Posted - 03/06/24

$NPCE is there a way to get 2026 options on this if so plz lmk. 😎

User Image swingingtech Posted - 03/05/24

$MNST $BIOX $DRCT $NPCE https://wallstreetwaves.com/financial-freedom-fighters-3-stocks-to-liberate-your-portfolio/

User Image cheating_stock_investor Posted - 03/05/24

$NPCE cash burn is manageable until they get cash flow positive. Still good value here for someone looking to have a long term multiple bagger return.

User Image DonCorleone77 Posted - 03/05/24

$NPCE NeuroPace sees FY24 revenue $73M-$77M, consensus $74.6M Sees FY24 gross margin 72%-74%. Sees FY24 operating expenses $80M-$84M. "We are energized by the strong momentum that was built in 2023 and look forward to continuing to both increase adoption and utilization of the RNS System and to expand access to RNS therapy in the large community of drug-resistant epilepsy patients while maintaining financial discipline," concluded Becker.

User Image DonCorleone77 Posted - 03/05/24

$NPCE NeuroPace reports Q4 EPS (23c), consensus (31c) Reports Q4 revenue $18.01M, consensus $17.46M. "This is an exciting period in our Company's history as we grew total revenue by 44% in 2023, which was driven by the execution of our strategy to expand market usage of our RNS System, while maintaining financial discipline and reducing our cash burn to $3.4 million in the fourth quarter," said Joel Becker, CEO of NeuroPace. "In 2023, we successfully implemented the first part of our three-part growth strategy for developing the market for our RNS System, aimed at increasing adoption across clinicians and expanding therapy utilization by current prescribers under what we call the 'modern RNS story.' We also successfully integrated DIXI Medical SEEG electrodes into our product portfolio and expanded sales throughout the year."

User Image Stock_Titan Posted - 03/05/24

$NPCE NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million https://www.stocktitan.net/news/NPCE/neuro-pace-announces-record-full-year-2023-revenue-of-65-4-m3up4ecze96o.html

User Image cheating_stock_investor Posted - 03/05/24

$NPCE unless suddenly the doctors dont want to implant i believe guidance will be strong. On jan 8 when they preannounced sales for 2023 with uptick on q4 sales numbers the price was around 12. So at 14s unless something turns out bad worse case is 12s; with guidance of double digit growth i expect it to continue higher from here. The lakestreet analyst gave a $22 target. I believe ceo joel becker was brought on board by activist shareholder to manage costs so we may reach profitability by year end and possibly be acquired at 40 dollars if the majority shareholders need to cash out. This is more than 50% owned by 3 funds.

User Image Joaquin_Guzman5 Posted - 03/05/24

$NPCE added

User Image Scoops1212 Posted - 03/04/24

$NPCE

User Image cheating_stock_investor Posted - 2 months ago

$NPCE i hear the community setting environment can get us to 100mil revenues this year. If so i expect we gain cash flow positive. Just fyi my price target here is 50 this year if they keep beating expectations. Should get official guidance next week.

User Image cheating_stock_investor Posted - 2 months ago

$NPCE https://www.sickkids.ca/en/news/archive/2024/sickkids-implants-the-first-responsive-neurostimulation-device-in-canada-to-treat-drug-resistant-epilepsy/ We should hear great things next week.

User Image Jbiv1971 Posted - 02/29/24

@cheating_stock_investor It’s a stock predictor that indicates a bullish-to-bearish reversal. $NPCE dropped soon after that.

User Image Jbiv1971 Posted - 02/28/24

$NPCE Head and shoulders?

Analyst Ratings
Wells Fargo Overweight Mar 14, 24
JP Morgan Overweight Mar 12, 24
Cantor Fitzgerald Overweight Mar 6, 24
Morgan Stanley Equal-Weight Mar 6, 24
Wells Fargo Equal-Weight Feb 22, 24
Leerink Partners Outperform Jan 30, 24
Lake Street Buy Dec 27, 23
Morgan Stanley Equal-Weight Dec 4, 23
Morgan Stanley Equal-Weight Nov 14, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Morrell Martha Chief Medical Office.. Chief Medical Officer Feb 02 Sell 15.12 17,589 265,946 77,762 02/06/24
Morrell Martha Chief Medical Office.. Chief Medical Officer Jan 30 Sell 15.07 13,848 208,689 95,351 02/01/24
Morrell Martha Chief Medical Office.. Chief Medical Officer Jan 24 Sell 15.01 828 12,428 109,199 01/26/24
Morrell Martha Chief Medical Office.. Chief Medical Officer Dec 26 Sell 10.06 13,402 134,824 110,027 12/28/23
KCK LTD. 10% Owner 10% Owner Nov 29 Sell 8.76 16,167 141,623 5,593,773 12/01/23
KCK LTD. Director Director Nov 27 Sell 8.86 11,171 98,975 5,609,940 11/29/23
ORBIMED ADVISORS LLC 10% Owner 10% Owner Oct 02 Sell 9.05 8,314 75,242 4,003,967 10/04/23
Kuhn Rebecca Chief Financial Offi.. Chief Financial Officer Oct 31 Option 0.03 1,428 43 59,704 11/02/22
LACOB JOSEPH Director Director Oct 18 Option 0.026 192 5 384 10/20/22
Ridley Irina General Counsel and.. General Counsel and Secretary Jun 08 Sell 5.778 2,500 14,445 61,139 06/09/22
Ridley Irina General Counsel and.. General Counsel and Secretary Feb 28 Sell 7.5386 1,470 11,082 6,652 03/01/22